Sigrun Thorsteinsdottir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sigrun Thorsteinsdottir has a total of 193 co-authors. Here are the top co-authors by number of shared publications:
- Sigurður Yngvi Kristinsson
Faculty of Medicine, University of Iceland, Reykjavik, Iceland
23 shared publications - Sæmundur Rögnvaldsson
Faculty of Medicine, University of Iceland, Reykjavik, Iceland
18 shared publications Stephen Harding
The Binding Site Group, Birmingham, UK
15 shared publications- Jón Þórir Óskarsson
Faculty of Medicine, University of Iceland, Reykjavik, Iceland
14 shared publications - Ola Landgren
Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, USA
12 shared publications Brian G. M. Durie
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Outpatient Cancer Center, Los Angeles, USA
11 shared publications
Latest Publications
- 10 October 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (29) , 2781-2786
Clinical and Psychological Outcomes After Monoclonal Gammopathy Screening: A Population-Based Screening Study and Subsequent Randomized Trial of Follow-Up
Multiple myeloma (MM) and related malignancies develop from an asymptomatic precursor condition, monoclonal gammopathy of undetermined significance (MGUS), detectable via blood testing. The benefits and harms of population-based MGUS screening remain uncertain. We conducted a nationwide screening study for monoclonal gammopathies and a randomized trial of follow-up strategies in Iceland (Iceland Screens, Treats, or Prevents Multiple Myeloma; ClinicalTrials.gov identifier: NCT03327597 ). In total, 75,422 (53% of those invited) were screened and those with MGUS (n = 3,541) were randomly assigned to no notification (arm 1), guideline-based follow-up (arm 2), or intensified follow-up (arm 3). Progression, symptom burden, and psychological well-being were compared between the control arm (arm 1) and intervention arms (arms 2 and 3). After a median follow-up of 4.5 years, screening led to a 27-fold increase in the detection of smoldering MM (8.6% v 0.3%; hazard ratio, 27.46 [95% CI, 10.21 to 73.86]; P < .001), but active malignancy rates did not differ. Active MM and related malignancy were diagnosed 1 year earlier in the intervention arms with fewer symptomatic presentations and hospitalizations at diagnosis. MGUS notification was not associated with adverse psychological outcomes. These findings demonstrate that population-based screening facilitates earlier detection of MM and expands access to early intervention without detectable psychological harm. Longer follow-up is required to determine the effects on survival and cost-effectiveness.
- 10 October 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (29) , 2781-2786
Clinical and Psychological Outcomes After Monoclonal Gammopathy Screening: A Population-Based Screening Study and Subsequent Randomized Trial of Follow-Up
Multiple myeloma (MM) and related malignancies develop from an asymptomatic precursor condition, monoclonal gammopathy of undetermined significance (MGUS), detectable via blood testing. The benefits and harms of population-based MGUS screening remain uncertain. We conducted a nationwide screening study for monoclonal gammopathies and a randomized trial of follow-up strategies in Iceland (Iceland Screens, Treats, or Prevents Multiple Myeloma; ClinicalTrials.gov identifier: NCT03327597 ). In total, 75,422 (53% of those invited) were screened and those with MGUS (n = 3,541) were randomly assigned to no notification (arm 1), guideline-based follow-up (arm 2), or intensified follow-up (arm 3). Progression, symptom burden, and psychological well-being were compared between the control arm (arm 1) and intervention arms (arms 2 and 3). After a median follow-up of 4.5 years, screening led to a 27-fold increase in the detection of smoldering MM (8.6% v 0.3%; hazard ratio, 27.46 [95% CI, 10.21 to 73.86]; P < .001), but active malignancy rates did not differ. Active MM and related malignancy were diagnosed 1 year earlier in the intervention arms with fewer symptomatic presentations and hospitalizations at diagnosis. MGUS notification was not associated with adverse psychological outcomes. These findings demonstrate that population-based screening facilitates earlier detection of MM and expands access to early intervention without detectable psychological harm. Longer follow-up is required to determine the effects on survival and cost-effectiveness.
- Open Access
- 18 July 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1)
Detailed immunophenotypic and genetic characterization of bone marrow clonal plasma cells and B-cells in early-stage monoclonal gammopathies
Monoclonal gammopathy (MG) of undetermined significance (MGUS) is the earliest and most prevalent stage of MG that may progress to symptomatic multiple myeloma (MM) or Waldenström’s macroglobulinemia (WM) through intermediate smoldering forms of both diseases. We used next-generation flow cytometry (NGF) to identify and purify bone marrow (BM) clonal plasma cells (cPC) and B-cells/lymphoplasmacytic cells (cB-cells) from 25 asymptomatic individuals with MG diagnosed within the population-based iStopMM screening program for further molecular analysis by next-generation sequencing (NGS). IgM-MGUS cases consistently exhibited WM-like phenotypes by NGF, and MYD88 p.L265P and/or CXCR4 mutations in the coexisting cPC and cB-cells. Conversely, cPC from non-IgM MGUS and smoldering MM (SMM) displayed a MM-like phenotype associated with genetic drivers –i.e., t(11;14)–, frequently coexisting with genetically unrelated cB-cells. Interestingly, recurrent RUNX1 single nucleotide variants were detected in cPC, but not coexisting cB-cells, from WM-like cases, suggesting a role for RUNX1 in PC differentiation. In summary, NGF enabled detailed immunophenotypic characterization of BM cPC and cB-cell populations in all cases analyzed, subdivided in IgM vs non-IgM cases with WM-like or MM-like phenotypic and genetic profiles, respectively. These findings underscore the potential contribution of NGF and NGS for accurate classification or early-stage disease, beyond conventional criteria.
- 18 July 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1)
Open AccessDetailed immunophenotypic and genetic characterization of bone marrow clonal plasma cells and B-cells in early-stage monoclonal gammopathies
Monoclonal gammopathy (MG) of undetermined significance (MGUS) is the earliest and most prevalent stage of MG that may progress to symptomatic multiple myeloma (MM) or Waldenström’s macroglobulinemia (WM) through intermediate smoldering forms of both diseases. We used next-generation flow cytometry (NGF) to identify and purify bone marrow (BM) clonal plasma cells (cPC) and B-cells/lymphoplasmacytic cells (cB-cells) from 25 asymptomatic individuals with MG diagnosed within the population-based iStopMM screening program for further molecular analysis by next-generation sequencing (NGS). IgM-MGUS cases consistently exhibited WM-like phenotypes by NGF, and MYD88 p.L265P and/or CXCR4 mutations in the coexisting cPC and cB-cells. Conversely, cPC from non-IgM MGUS and smoldering MM (SMM) displayed a MM-like phenotype associated with genetic drivers –i.e., t(11;14)–, frequently coexisting with genetically unrelated cB-cells. Interestingly, recurrent RUNX1 single nucleotide variants were detected in cPC, but not coexisting cB-cells, from WM-like cases, suggesting a role for RUNX1 in PC differentiation. In summary, NGF enabled detailed immunophenotypic characterization of BM cPC and cB-cell populations in all cases analyzed, subdivided in IgM vs non-IgM cases with WM-like or MM-like phenotypic and genetic profiles, respectively. These findings underscore the potential contribution of NGF and NGS for accurate classification or early-stage disease, beyond conventional criteria.
- Open Access
- 6 July 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (9) , 2043-2047
Redefining light-chain smoldering multiple myeloma: prevalence and progression risk
- 6 July 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (9) , 2043-2047
Open AccessRedefining light-chain smoldering multiple myeloma: prevalence and progression risk
- Open Access
- 11 April 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1)
Impact of SARS-CoV-2 vaccination on monoclonal gammopathy of undetermined significance: results from the population-based iStopMM study
- 11 April 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1)
Open AccessImpact of SARS-CoV-2 vaccination on monoclonal gammopathy of undetermined significance: results from the population-based iStopMM study
- Open Access
- 8 April 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1)
Dietary intake and the risk of monoclonal gammopathy of undetermined significance: results from the population-based iStopMM screening study
Monoclonal gammopathy of undetermined significance (MGUS) is the asymptomatic precursor of multiple myeloma (MM) and related disorders. Understanding the causes of MGUS is key to elucidating the causes of these malignancies. The association of MGUS and diet, including dietary patterns, remains unclear. We therefore assessed the relationship between diet and MGUS in the iStopMM a nationwide screening study for MGUS in Iceland where 75,422 individuals have been screened for MGUS. A food-frequency questionnaire was distributed to participants with 27,217 respondents, of whom 1,020 had MGUS at screening. Exposure was defined as dietary intake of specific dietary items and adherence to five dietary patterns identified through principal component analysis. Logistic regression was used to calculate odds ratios (OR) of having MGUS, adjusting for age, sex, physical activity, and education. No dietary patterns nor specific dietary components were associated with risk of MGUS overall. However, high consumption of dairy products was associated with increased odds (OR 2.01, 95% CI 1.16-3.65) of IgA MGUS, even after adjusting for multiple comparisons. These findings suggest that dietary habits are not a major risk factor for MGUS overall and therefore unlikely to be a major causative factor in the development of MM.
- 8 April 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1)
Open AccessDietary intake and the risk of monoclonal gammopathy of undetermined significance: results from the population-based iStopMM screening study
Monoclonal gammopathy of undetermined significance (MGUS) is the asymptomatic precursor of multiple myeloma (MM) and related disorders. Understanding the causes of MGUS is key to elucidating the causes of these malignancies. The association of MGUS and diet, including dietary patterns, remains unclear. We therefore assessed the relationship between diet and MGUS in the iStopMM a nationwide screening study for MGUS in Iceland where 75,422 individuals have been screened for MGUS. A food-frequency questionnaire was distributed to participants with 27,217 respondents, of whom 1,020 had MGUS at screening. Exposure was defined as dietary intake of specific dietary items and adherence to five dietary patterns identified through principal component analysis. Logistic regression was used to calculate odds ratios (OR) of having MGUS, adjusting for age, sex, physical activity, and education. No dietary patterns nor specific dietary components were associated with risk of MGUS overall. However, high consumption of dairy products was associated with increased odds (OR 2.01, 95% CI 1.16-3.65) of IgA MGUS, even after adjusting for multiple comparisons. These findings suggest that dietary habits are not a major risk factor for MGUS overall and therefore unlikely to be a major causative factor in the development of MM.
- Open Access
- 30 March 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1)
Revised criteria for light chain MGUS enhance diagnostic accuracy and risk stratification
Light chain monoclonal gammopathy of undetermined significance (LC-MGUS) is an asymptomatic precursor of multiple myeloma (MM) and related disorders defined by abnormal free light chain (FLC) testing. Recently, revised FLC reference intervals were proposed by the iStopMM study group. We evaluated their performance in a large population-based cohort. MGUS cases were identified from the Danish Lymphoid Cancer Research (DALY-CARE) data resource, including only individuals with Freelite FLC-measurements. Cases were classified by original and revised LC-MGUS criteria, hereby identifying cases only fulfilling original but not revised criteria (reclassified as normal). Outcomes were progression to MM or related disorders. Cumulative incidence of progression with death as competing risk was examined using Aalen-Johansen estimation. Annual progression risk was assessed using a person-years approach. In total, 360 individuals classified by original criteria, 215 by revised, while 150 (40%) were reclassified as normal. In the revised group, there were 21 (9.8%) progressions; 11 (5.1%) to MM and seven (3.3%) to AL amyloidosis. Only two individuals (1.3%) progressed in the reclassified group, none to MM or AL amyloidosis. For revised LC-MGUS, the 2- and 5-year cumulative incidence of progression was 5.8% and 8.9%, respectively, with an annual progression rate of 3%. This study validates the performance of the iStopMM revised LC-MGUS criteria in a clinical cohort. Applying the revised criteria reduced LC-MGUS diagnoses by 40% without missing cases progressing to MM or AL amyloidosis. These findings confirm the accuracy of the revised criteria and support their implementation to improve diagnostics and ensure follow-up of individuals truly at risk.
- 30 March 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1)
Open AccessRevised criteria for light chain MGUS enhance diagnostic accuracy and risk stratification
Light chain monoclonal gammopathy of undetermined significance (LC-MGUS) is an asymptomatic precursor of multiple myeloma (MM) and related disorders defined by abnormal free light chain (FLC) testing. Recently, revised FLC reference intervals were proposed by the iStopMM study group. We evaluated their performance in a large population-based cohort. MGUS cases were identified from the Danish Lymphoid Cancer Research (DALY-CARE) data resource, including only individuals with Freelite FLC-measurements. Cases were classified by original and revised LC-MGUS criteria, hereby identifying cases only fulfilling original but not revised criteria (reclassified as normal). Outcomes were progression to MM or related disorders. Cumulative incidence of progression with death as competing risk was examined using Aalen-Johansen estimation. Annual progression risk was assessed using a person-years approach. In total, 360 individuals classified by original criteria, 215 by revised, while 150 (40%) were reclassified as normal. In the revised group, there were 21 (9.8%) progressions; 11 (5.1%) to MM and seven (3.3%) to AL amyloidosis. Only two individuals (1.3%) progressed in the reclassified group, none to MM or AL amyloidosis. For revised LC-MGUS, the 2- and 5-year cumulative incidence of progression was 5.8% and 8.9%, respectively, with an annual progression rate of 3%. This study validates the performance of the iStopMM revised LC-MGUS criteria in a clinical cohort. Applying the revised criteria reduced LC-MGUS diagnoses by 40% without missing cases progressing to MM or AL amyloidosis. These findings confirm the accuracy of the revised criteria and support their implementation to improve diagnostics and ensure follow-up of individuals truly at risk.
- Open Access
- 12 September 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (12) , 2997-3003
Increased risk of infections in smoldering multiple myeloma: results from the screened iStopMM study
Infections are a major cause of morbidity and mortality in multiple myeloma (MM). While increased infection risk has been shown in monoclonal gammopathy of undetermined significance (MGUS), data are limited for smoldering multiple myeloma (SMM). We used data from the iStopMM study, which screened 75,422 Icelandic individuals aged ≥40 years for MM precursors. Individuals diagnosed with SMM were matched by age and sex with MGUS-free comparators (1:5 ratio) and with individuals with MGUS (1:1 ratio). Infection outcomes were derived from nationwide registries of ICD-10 diagnostic codes and antimicrobial prescriptions. Cox proportional hazards models estimated infection risk, adjusted for immunoparesis. 188 SMM individuals were matched to 188 MGUS individuals and 162 SMM individuals were matched to 810 comparators. Individuals with SMM had significantly more infections (HR 1.36, 95% CI 1.07–1.73) and antibacterial prescriptions (HR 1.24, 95% CI 1.01–1.52) than the comparators. Compared to MGUS, individuals with SMM also had more infections (HR 1.37, 95% CI 1.00–1.87). Adjusting for immunoparesis attenuated the associations, suggesting it may partially mediate infection risk. This first screened cohort of SMM shows a significantly increased infection risk, compared to both MGUS and to individuals without MM precursors, suggesting an underrecognized infection burden in SMM.
- 12 September 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (12) , 2997-3003
Open AccessIncreased risk of infections in smoldering multiple myeloma: results from the screened iStopMM study
Infections are a major cause of morbidity and mortality in multiple myeloma (MM). While increased infection risk has been shown in monoclonal gammopathy of undetermined significance (MGUS), data are limited for smoldering multiple myeloma (SMM). We used data from the iStopMM study, which screened 75,422 Icelandic individuals aged ≥40 years for MM precursors. Individuals diagnosed with SMM were matched by age and sex with MGUS-free comparators (1:5 ratio) and with individuals with MGUS (1:1 ratio). Infection outcomes were derived from nationwide registries of ICD-10 diagnostic codes and antimicrobial prescriptions. Cox proportional hazards models estimated infection risk, adjusted for immunoparesis. 188 SMM individuals were matched to 188 MGUS individuals and 162 SMM individuals were matched to 810 comparators. Individuals with SMM had significantly more infections (HR 1.36, 95% CI 1.07–1.73) and antibacterial prescriptions (HR 1.24, 95% CI 1.01–1.52) than the comparators. Compared to MGUS, individuals with SMM also had more infections (HR 1.37, 95% CI 1.00–1.87). Adjusting for immunoparesis attenuated the associations, suggesting it may partially mediate infection risk. This first screened cohort of SMM shows a significantly increased infection risk, compared to both MGUS and to individuals without MM precursors, suggesting an underrecognized infection burden in SMM.
- Open Access
- 23 July 2025
- Published by Wiley in British Journal of Haematology
- Vol. 207 (4) , 1638-1642
Cytogenetic abnormalities in multiple myeloma patients according to age: A real‐world study by the Nordic Myeloma Study Group
- 23 July 2025
- Published by Wiley in British Journal of Haematology
- Vol. 207 (4) , 1638-1642
Open AccessCytogenetic abnormalities in multiple myeloma patients according to age: A real‐world study by the Nordic Myeloma Study Group
- Open Access
- 27 May 2025
- Published by Springer Nature in Blood Cancer Journal
- Vol. 15 (1) , 1
Correction: Revised free light chain reference intervals enhance risk stratification in monoclonal gammopathy of undetermined significance and reduce overdiagnosis
- 27 May 2025
- Published by Springer Nature in Blood Cancer Journal
- Vol. 15 (1) , 1
Open AccessCorrection: Revised free light chain reference intervals enhance risk stratification in monoclonal gammopathy of undetermined significance and reduce overdiagnosis
- Open Access
- 28 April 2025
- Published by Springer Nature in Blood Cancer Journal
- Vol. 15 (1) , 1-8
Revised free light chain reference intervals enhance risk stratification in monoclonal gammopathy of undetermined significance and reduce overdiagnosis
The free light chain (FLC) ratio is a critical part of risk stratification for monoclonal gammopathy of undetermined significance (MGUS). Recently, revised FLC reference intervals developed using the iStopMM cohort, accounting for age and renal function, have reduced the rate of abnormal findings. Here, we examine the implications of the revision in an independent Danish MGUS cohort. Of 6993 MGUS individuals, 2641 had an abnormal FLC ratio by the original intervals, of whom 844 (32%) were reclassified as normal using the revised intervals. Reclassified individuals had no significantly increased risk of progression compared to those with a normal FLC ratio (hazard ratio (HR): 1.07, 95% confidence interval (CI) 0.74–1.57). Those with an abnormal FLC ratio by the revised reference intervals had an increased risk of progression (HR 2.23, 95% CI 1.79–2.78). Using the revised reference intervals, 490 individuals (16%) were reclassified to low-risk from a higher risk group. These individuals had a similar progression risk compared to others in the low-risk group. The findings validate the revised FLC reference intervals, enhancing prognostic accuracy and improving risk stratification to accurately identify MGUS individuals at risk of progression while reducing unnecessary classifications as high-risk.
- 28 April 2025
- Published by Springer Nature in Blood Cancer Journal
- Vol. 15 (1) , 1-8
Open AccessRevised free light chain reference intervals enhance risk stratification in monoclonal gammopathy of undetermined significance and reduce overdiagnosis
The free light chain (FLC) ratio is a critical part of risk stratification for monoclonal gammopathy of undetermined significance (MGUS). Recently, revised FLC reference intervals developed using the iStopMM cohort, accounting for age and renal function, have reduced the rate of abnormal findings. Here, we examine the implications of the revision in an independent Danish MGUS cohort. Of 6993 MGUS individuals, 2641 had an abnormal FLC ratio by the original intervals, of whom 844 (32%) were reclassified as normal using the revised intervals. Reclassified individuals had no significantly increased risk of progression compared to those with a normal FLC ratio (hazard ratio (HR): 1.07, 95% confidence interval (CI) 0.74–1.57). Those with an abnormal FLC ratio by the revised reference intervals had an increased risk of progression (HR 2.23, 95% CI 1.79–2.78). Using the revised reference intervals, 490 individuals (16%) were reclassified to low-risk from a higher risk group. These individuals had a similar progression risk compared to others in the low-risk group. The findings validate the revised FLC reference intervals, enhancing prognostic accuracy and improving risk stratification to accurately identify MGUS individuals at risk of progression while reducing unnecessary classifications as high-risk.